191 related articles for article (PubMed ID: 19092780)
1. Pharmacokinetic considerations for new targeted therapies.
Baker SD; Hu S
Clin Pharmacol Ther; 2009 Feb; 85(2):208-11. PubMed ID: 19092780
[TBL] [Abstract][Full Text] [Related]
2. Protein kinases as targets for cancer treatment.
Giamas G; Stebbing J; Vorgias CE; Knippschild U
Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
[TBL] [Abstract][Full Text] [Related]
3. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations.
Ho HK; Yeo AH; Kang TS; Chua BT
Drug Discov Today; 2014 Jan; 19(1):51-62. PubMed ID: 23932951
[TBL] [Abstract][Full Text] [Related]
4. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors.
Foroughi-Nia B; Barar J; Memar MY; Aghanejad A; Davaran S
Life Sci; 2021 Aug; 278():119642. PubMed ID: 34033837
[TBL] [Abstract][Full Text] [Related]
5. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
[TBL] [Abstract][Full Text] [Related]
6. Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
van Beuge MM; Poelstra K; Prakash J
Expert Opin Drug Deliv; 2012 Jan; 9(1):59-70. PubMed ID: 22111941
[TBL] [Abstract][Full Text] [Related]
7. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.
Miyashita K; Nakada M; Shakoori A; Ishigaki Y; Shimasaki T; Motoo Y; Kawakami K; Minamoto T
Anticancer Agents Med Chem; 2009 Dec; 9(10):1114-22. PubMed ID: 19925395
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in the treatment of cancer.
Meisheid AM
J Contin Educ Nurs; 2005; 36(5):193-4. PubMed ID: 16218004
[No Abstract] [Full Text] [Related]
9. Targeted therapies and biological modifiers. Introduction.
de Alava E
Semin Diagn Pathol; 2008 Nov; 25(4):231. PubMed ID: 19013889
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic considerations for targeted drug delivery.
Yamashita F; Hashida M
Adv Drug Deliv Rev; 2013 Jan; 65(1):139-47. PubMed ID: 23280371
[TBL] [Abstract][Full Text] [Related]
11. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
Baselga J
Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
[No Abstract] [Full Text] [Related]
12. Changes and challenges--the world post-Gleevec (Glivec).
Hickman JA; Lazo JS
Curr Opin Pharmacol; 2002 Aug; 2(4):357-60. PubMed ID: 12127866
[No Abstract] [Full Text] [Related]
13. Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation.
Liu MC; Marshall JL; Pestell RG
Curr Cancer Drug Targets; 2004 Aug; 4(5):403-24. PubMed ID: 15320717
[TBL] [Abstract][Full Text] [Related]
14. c-Jun N-terminal kinases as potential therapeutic targets.
Salh B
Expert Opin Ther Targets; 2007 Oct; 11(10):1339-53. PubMed ID: 17907963
[TBL] [Abstract][Full Text] [Related]
15. Safety of Novel Targeted Therapies in Oncology.
Shah RR; Curigliano G
Drug Saf; 2019 Feb; 42(2):157-158. PubMed ID: 30649739
[No Abstract] [Full Text] [Related]
16. Protein kinases as targets for antiparasitic chemotherapy drugs.
Canduri F; Perez PC; Caceres RA; de Azevedo WF
Curr Drug Targets; 2007 Mar; 8(3):389-98. PubMed ID: 17348832
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine kinase inhibitors: new treatment modalities?
Fabbro D; Parkinson D; Matter A
Curr Opin Pharmacol; 2002 Aug; 2(4):374-81. PubMed ID: 12127869
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors: promises and realities.
Cox AD; Der CJ
Curr Opin Pharmacol; 2002 Aug; 2(4):388-93. PubMed ID: 12127871
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery strategies in targeting cancer: current concepts and future developments.
Arias JL
Curr Drug Targets; 2011 Jul; 12(8):1094-5. PubMed ID: 21443479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
